Accelerated cellular aging caused by methamphetamine use limited in lab

With funding from the National Institute on Drug Abuse to probe the effects of methamphetamine on the "lipidome" (the complete lipid profile of representative organs and tissues) in rats that self-administer the drug, UCI's Daniele Piomelli and his IIT colleagues found that its use caused abnormalities in cellular fat metabolism, triggering extreme inflammation marked by a considerable rise in the formation of ceramides, pro-inflammatory molecules that can foster cell aging and death.

Study results appear in the open-access online journal PLOS ONE.

Methamphetamine is a highly addictive psychostimulant that profoundly damages the brain and other body organs. Postmortem examinations of human tissues have linked use of the drug to diseases associated with aging, such as coronary atherosclerosis and pulmonary fibrosis, but the molecular mechanisms underlying these findings have remained unknown.

The Piomelli team learned that this cellular cascade involves the recruitment of nuclear factor kappa beta, a protein that under healthy conditions helps control DNA encoding of proteins. But as the cell is flooded with methamphetamine-induced signaling, nuclear factor kappa beta triggers excessive signaling in pathways that engender dramatic increases in ceramide activity.

"We found this signaling process to be key for advanced cellular aging, which is at the heart of the accelerated aging influenced by methamphetamine abuse," said Piomelli, the Louise Turner Arnold Chair in the Neurosciences.

Having identified these mechanisms, the researchers tested existing inhibitors of nuclear factor kappa beta signaling, which succeeded in limiting ceramide formation. This prevented methamphetamine-induced cell aging and systemic inflammation in rats self-administering the drug, curtailing their health deterioration.

"These results suggest new therapeutic strategies to reduce the adverse consequences of methamphetamine abuse and improve the effectiveness of abstinence treatments," Piomelli said.

He is currently working with colleagues at the Italian Institute of Technology, in Genoa, to create a pharmaceutical application of these inhibitor compounds.